Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-MCAM Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells

Authors

W Luo, New York Medical CollegeFollow
A Gardenswartz, New York Medical CollegeFollow
Y Chu, New York Medical CollegeFollow
J M. Rosenblum, New York Medical CollegeFollow
J Ayello, New York Medical CollegeFollow
M Marcondes
W W. Overwijk
T P. Cripe
K A. Cassady
D A. LeeFollow
M S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

2022

DOI

10.1002/pbc.29735

Journal Title

Pediatric Blood and Cancer

Department

Pediatrics

Abstract

Background: Pediatric patients with metastatic ES, OS and NB have a dismal average 5-year survival (

Disciplines

Medicine and Health Sciences

Recommended Citation

Luo, W., Gardenswartz, A., Chu, Y., Rosenblum, J. M., Ayello, J., Marcondes, M., Overwijk, W. W., Cripe, T. P., Cassady, K. A., Lee, D. A., & Cairo, M. S. (2022). Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-MCAM Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells. Pediatric Blood and Cancer, 69 (Suppl. 2), S220-S221. https://doi.org/10.1002/pbc.29735